Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier

Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.

AAndy Scharenberg MMichael Jensen UUmoja Biopharma UUniversity of Washington